EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.

Last week, at the Heart Valve Society Meeting ... best treated with Edwards premium RESILIA portfolio, including MITRIS, INSPIRIS, and KONECT. We continue to generate high-quality evidence ...

In the first quarter of 2025, the segment grew 1% from the prior-year level, driven by strong global adoption of Edwards’ premium surgical technologies, INSPIRIS ... valves at the Heart Valve ...

Transcatheter Aortic Valve Replacement (TAVR ... for the many patients best treated with Edwards’ premium RESILIA tissue portfolio including MITRIS, INSPIRIS and KONECT. Also in the first ...

With EVOQUE, SAPIEN M3 and PASCAL, Edwards is uniquely positioned to meet the broad and diverse needs of patients with tricuspid and mitral valve diseases. Surgical In Surgical, first quarter ...

TMTT sales guidance for 2025 has been raised to $530 million to $550 million, citing strong momentum in tricuspid and mitral valve technologies ... including MITRIS and INSPIRIS, continues ...

Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS).